What is Cartesian Therapeutics Inc.?
, a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
, a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 193.69M.
A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.